Sandoz Bolsters its European Essential Medicine Manufacturing Capacity
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Address: Bürohaus Neue Donau,
Wagramer Str. 4/OG 7/ Top 7
1220 Wien
,Austria
Tel: 0043-(0)171728313
Web: http://www.krka.biz/en/?utm_source=301
Krka is among top generic pharmaceutical companies in the world. We have now been successfully implementing our strategies and pursuing our mission and vision for over half a century.
Line of business
Krka’s basic line of business is the production and sale of prescription pharmaceuticals, non-prescription products and animal health products. The company’s activities are supplemented by health resort and tourist services.
Markets
Our products are sold in over 70 countries. As part of our business strategy we have set the objective of balanced sales in five different regions: Slovenia, Central Europe, South-East Europe, East Europe, West Europe and Overseas Markets.
Research and development
At Krka we develop innovative generic medicines, i.e. generic medicines with value added, which are the product of our own in-house knowledge, and provide our products with major advantages for years after market entry. All our pharmaceuticals offer high quality, efficacy and safety. Our products are marketed under our own brands.
Quality
As a generic producer, Krka is responsible for medicines that can take their place alongside the world’s leading pharmaceutical companies in terms of quality, safety and efficacy. Quality, in the broadest sense of the word, is created, maintained, and the responsibility of all employees. Krka’s systematic approach is intended to ensure it exceeds customer requirements and achieve its set operating objectives.
Investment
Krka’s strategy for own-brand generic pharmaceutical development is achieved through investment in research and development capacity and Krka’s own production and distribution centres around the world.
Employee care
Krka’s business performance is based on the commitment and the knowledge of its employees. At Krka we are committed to acquiring, motivating and retaining dedicated and capable staff and building an international corporate culture. Investment in knowledge and the development of all our employees helps them to become among the very best in their own fields of work.
Prescription pharmaceuticals
Krka’s prescription pharmaceuticals are, in the great majority, the result of our own knowledge, since these are high quality generic products with added value.
Non-prescription products
Krka has an extensive portfolio of non-prescription products covering all key indications for self-medication for which people frequently seek non-prescription medications to alleviate the symptoms.
Animal health products
In the animal health field, we have more than 50 registered products. These are mainly products which act against the causative agents of infectious and parasitic diseases, feed additives, …
In the wake of the COVID-19 crisis and the subsequent strain placed on medicine supply chains in Europe, Sandoz – the generics arm of global giant Novartis – has moved…
Albin Egger, country representative of UCB Pharma Austria, discusses the strong performance of the Austrian affiliate within the global group, organizational restructuring, and the receptiveness of Austria to UCB’s innovative…
Joy Ladurner, co-director of the NKSE (National Coordination Center for Rare Diseases) in Austria, discusses the rationale behind Austria’s prioritization of rare diseases and its leading role in the field.…
Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out,…
Gerhard Hirczi of the Vienna Business Agency and Peter Halwachs of LISAvienna describe Vienna’s impressive footprint in the life sciences, its positioning as the start-up hub for Central and Eastern…
Peter Wimmer, country manager of Angelini Austria and Germany, discusses the tailored long-term strategy that this exciting Italian pharmaceutical company is implementing to establish a boutique portfolio and the importance…
Christoph Wahl and Gerlad Weirowski of DHL Global Forwarding Austria discuss the significance of the Austrian affiliate being chosen as lead office for CEE and the company’s life sciences and…
Christoph Sauermann, managing director of Mediclass, an innovative healthcare center, discusses how the complexities of the Austrian healthcare system can be solved through primary healthcare centers, such as Mediclass. Furthermore,…
Rudolf Widmann, CEO and founder of AOP Orphan, the first rare disease-specific European company, discusses the overriding goal to ensure rare disease patients are matched with the correct treatments and…
Barbara Rangetiner and Josef Weinberger of the Austrian affiliate of Octapharma, the largest privately owned human protein products manufacturer in the world, discuss the strategic significance of Austria to the…
Dr. Wolfgang Harrer, regional manager of Chiesi Central and Eastern Europe (CEE), discusses the challenges of managing the region’s diverse cultural differences and the importance of CEE within global operations.…
David Kasper, CEO of ARCHIMEDlife, an innovative Austrian company focused on novel laboratory diagnostics, discusses the innovative solution of a dried blood sample in daily routine diagnostics and novel assays…
See our Cookie Privacy Policy Here